SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 2 of 34 
 SAP REVISION  HISTORY  
Version  Date  Description  of Changes  
1.0 05 Sep 2019  Initial version  
   
 
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 3 of 34 
 Table of Contents  
1. Introduction  ................................ ................................ ................................ ...........................  5 
2. Study Design  ................................ ................................ ................................ ..........................  5 
2.1 Overview  ................................ ................................ ................................ ................................ .........................  5 
2.2 Study Objectives  ................................ ................................ ................................ ................................ .............  5 
2.3 Study Population  ................................ ................................ ................................ ................................ .............  6 
2.4 Participan t Flow  ................................ ................................ ................................ ................................ ..............  6 
2.5 Treatment Allocation  ................................ ................................ ................................ ................................ ....... 7 
2.6 Treatment Administration  ................................ ................................ ................................ ...............................  7 
2.7 Allocation Concealment  ................................ ................................ ................................ ................................ .. 7 
2.8 Schedule of Assessments ................................ ................................ ................................ ................................ . 8 
3. Statistical Design  ................................ ................................ ................................ ...................  9 
3.1 Primary Outcome  ................................ ................................ ................................ ................................ ............  9 
3.2 Efficacy Outcomes  ................................ ................................ ................................ ................................ ..........  9 
3.3 Safety O utcomes  ................................ ................................ ................................ ................................ .............  9 
3.4 Tolerability  ................................ ................................ ................................ ................................ ....................  10 
3.5 Symptomatic Effects  ................................ ................................ ................................ ................................ ..... 10 
3.6 Two-period Evaluations  ................................ ................................ ................................ ................................  10 
3.7 Effect Size for Primary Outcome  ................................ ................................ ................................ ..................  10 
3.8 Sample Size  ................................ ................................ ................................ ................................ ...................  11 
3.9 Power for Secondary Outcomes  ................................ ................................ ................................ ....................  12 
4. Baseline Characteristics, Study Endpoints, and Final Disposition  ................................  13 
4.1 Baseline Characteristics  ................................ ................................ ................................ ................................  13 
4.2 Expectancy and Treatment Preference  ................................ ................................ ................................ ..........  13 
4.3 Efficacy Endpoints  ................................ ................................ ................................ ................................ ........  13 
4.4 Intervention and Pharmacodynamic Endpoints  ................................ ................................ .............................  14 
4.5 Safety Endpoints  ................................ ................................ ................................ ................................ ...........  14 
4.6 Tolerability Endpoint  ................................ ................................ ................................ ................................ .... 15 
4.7 Blinding  ................................ ................................ ................................ ................................ .........................  15 
4.8 Final Dispositio n ................................ ................................ ................................ ................................ ...........  15 
5. Measurement Definitions  ................................ ................................ ................................ ... 15 
5.1 Movement Disorders Society Unified PD Rating Scale (MDS -UPDRS)  ................................ .....................  15 
5.2 Modified Schwab & England Activities of Daily Living Scale  ................................ ................................ .... 16 
5.3 Parkinson’s Disease Question naire - 39 item version (PDQ -39) scale  ................................ ..........................  17 
5.4 Modified Hoehn and Yahr Scale  ................................ ................................ ................................ ...................  17 
5.5 Assess Need for Dopaminergic Therapy  ................................ ................................ ................................ ....... 17 
5.6 Mini -Mental State Examination (MMSE)  ................................ ................................ ................................ ..... 17 
5.7 Montreal Cognitive Assessment (MoCA)  ................................ ................................ ................................ ..... 18 
5.8 Quality of Life in Neurological Disorders (Neuro -QOL)  ................................ ................................ ..............  18 
5.9 Initiation of Dopaminergic Therapy  ................................ ................................ ................................ ..............  19 
5.10 Primary Diagnosis Assessment ................................ ................................ ................................ .................  19 
5.11 Diagnostic Features Assessment ................................ ................................ ................................ ...............  19 
5.12 Dopamine Transporter (DAT) Neuroimaging  ................................ ................................ ..........................  19 
5.13 Orthostasis  ................................ ................................ ................................ ................................ ................  20 
5.14 Levodopa Eq uivalent Daily Dosage  ................................ ................................ ................................ .........  20 
5.15 Blindedness Evaluation  ................................ ................................ ................................ ............................  21 
5.16 Genetics  ................................ ................................ ................................ ................................ ....................  22 
5.17 Exploratory Assessments  ................................ ................................ ................................ ..........................  22 
6. Statistical Methodology  ................................ ................................ ................................ ...... 23 
6.1 General Considerations  ................................ ................................ ................................ ................................ . 23 
6.1.1 Statistical Software  ................................ ................................ ................................ ..............................  23 
6.1.2 Summary Statistics  ................................ ................................ ................................ ..............................  23 
6.1.3 Precision  ................................ ................................ ................................ ................................ ..............  23 
6.1.4 Administration  ................................ ................................ ................................ ................................ ..... 23 
6.2 Analysis  Samples  ................................ ................................ ................................ ................................ ..........  23 
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 4 of 34 
 6.3 Baseline Comparison  ................................ ................................ ................................ ................................ ..... 24 
6.4 Sample Size Review  ................................ ................................ ................................ ................................ ...... 24 
6.5 Interi m Analysis  ................................ ................................ ................................ ................................ ............  24 
6.6 Efficacy Analysis  ................................ ................................ ................................ ................................ ..........  25 
6.6.1 Primary Analysis of the Primary Efficacy Endpoint  ................................ ................................ ............  25 
6.6.2 Secondary Analyses of the Primary Effi cacy Endpoint  ................................ ................................ ....... 25 
6.6.3 Secondary Efficacy Endpoints  ................................ ................................ ................................ .............  26 
6.6.4 Disability Warranting Dopaminergic Therapy ................................ ................................ .....................  26 
6.6.5 Combined Function and Treatment  ................................ ................................ ................................ ..... 26 
6.6.6 Subgroup Analyses  ................................ ................................ ................................ ..............................  27 
6.6.7 Pharmacogenetics  ................................ ................................ ................................ ................................  27 
6.6.8 Symptomatic Effects  ................................ ................................ ................................ ............................  27 
6.6.9 Disease Modification  ................................ ................................ ................................ ...........................  28 
6.6.10  Multiplicity Adjustments  ................................ ................................ ................................ .....................  28 
6.6.11 Missing Data  ................................ ................................ ................................ ................................ ........  28 
6.7 Safety and Tolerability Analysis  ................................ ................................ ................................ ...................  28 
6.7.1 Treatment -emergent Adverse Events  ................................ ................................ ................................ ... 28 
6.7.2 Safety Labs  ................................ ................................ ................................ ................................ ..........  29 
6.7.3 Vital Signs  ................................ ................................ ................................ ................................ ...........  29 
6.7.4 Additional Continuous Safety Outcomes  ................................ ................................ .............................  29 
6.7.5 Tolerability  ................................ ................................ ................................ ................................ ..........  29 
6.7.6 Alkalini zation and Nephrolithiasis  ................................ ................................ ................................ ...... 29 
6.8 Other Analyses  ................................ ................................ ................................ ................................ ..............  30 
6.8.1 Participant Disposition  ................................ ................................ ................................ .........................  30 
6.8.2 Study Drug Exposure  ................................ ................................ ................................ ...........................  30 
6.8.3 Prior and Concomitant Medication Use  ................................ ................................ ...............................  30 
6.8.4 Determinants of change in MDS -UPDRS  ................................ ................................ ...........................  30 
6.8.5 Determinants of Early Disability Warranting Dopaminergic Therapy  ................................ ................  31 
6.8.6 Placebo Response  ................................ ................................ ................................ ................................  31 
6.8.7 Blindedness  ................................ ................................ ................................ ................................ ..........  32 
7. References  ................................ ................................ ................................ ............................  32 
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 5 of 34 
 1. Introduction  
This statistical analysis plan (SAP)  defines the  outcome measures and analysis samples  and 
specifies the  planned analyse s of data  for the SURE -PD3 trial. The SAP supplements the clinical 
protocol. Please  refer to  the clinical protocol for details on the  rationale for the intervention, 
eligibility criteria,  conduct of the trial , clinical assessment s and the timing of their use i n the trial,  
definitions and reporting  of adverse events, data management  conventions , and regulatory 
oversight and compliance procedures . In case of discrepancies between the SAP and the clinical 
protocol concern ing matters of data analysis, the SAP is authoritative. On all other matters, the  
clinical protocol is authoritative.  
This SAP specifies data and planned analyses for the main trial. Specification of data and 
analyses for a ncillary studies will be detailed in ancillary SAPs  if not covered here . 
2. Study Design  
2.1 Overview  
This is a phase 3, randomized, two -arm, parallel -group, placebo -controlled, triple -blind, two-
period, multicenter clinical trial of oral inosine titrated to elevate trough serum urate to 7.1 to 8.0 
mg/dL over 24 months with a 3 -month wash -out among early  Parkinson disease ( PD) patients 
exclusive of those with scans  without evidence of dopaminergic deficit (SWEDD) . The primary 
aim is to test the effectiveness of oral inosine dosed to elevate serum urate in slowing or delaying 
PD progression over 24 months  based on rate of chan ge in the Movement Disorders Society 
Uniform Parkinson's Disease Rating Scale ( MDS -UPDRS ) Parts I-III total score  while 
participants are not receiving dopaminergic therapy (except possibly a stable dosage  of a 
monoamine oxidase -B [MAO -B] inhibitor at baseline) . Randomizations are stratified by site to 
avoid chance confounding between site characteristics and treatment.  The trial is registered at 
Clinicaltrials.gov as study [STUDY_ID_REMOVED]  (see https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED] ). 
The randomized, two -arm, parallel -group design provide s an unbiased estimate of effectiveness 
of oral inosine dosed to elevate serum urate in slowing or delaying PD progression over 24 
months during period 1. Tracking symptoms during randomized wash -in an d during the non -
randomized 3 -month wash -out of period 2 will allow estimation of symptomatic effects of serum 
urate elevation and thereby better evaluate whether any observed effects on PD progression 
reflect a disease -modifying effect. Note that although  suspension of study drug during the wash -
out will be unmasked, subjects and staff will remain blinded as to whether this represents a 
transition off of active treatment or of placebo treatment, and thus treatment comparison of 
changes during the 3 -month w ash-out should remain unbiased. The difference in the proportion 
of subjects requiring dopaminergic therapy after the 3 -month wash -out among all those 
randomized will provide an estimate of disease -modification by serum urate elevation free of any 
symptoma tic effects of study drug.  
2.2 Study Objectives  
The p rimary objective of the trial is to determine whether  oral inosine dosed to elevate serum 
urate is effective in slowing or delaying PD progression over 24 months . Secondary objectives 
include evaluating the safety and tolerability  of serum urate elevation , determining whether 
serum urate elevation  causes short -term, reversible effects on clinical symptoms, and whether 
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 6 of 34 
 serum urate elevation is effective in delaying time to  need for or initiation of dopaminergi c 
therapy or in slowing worsening  of cognitive  function , mood, autonomic function , quality of life, 
or functional disability . 
2.3 Study Population  
Individuals eligible for trial participation are m en or women age 30  years  or older with early 
idiopathic PD , serum urate ≤5.7 mg/dL, with evidence of dopamine deficit  by dopamin e 
transporter brain scan , and free of risk factors for potential urate -related adverse events (AEs) . 
Early PD requires a modified Hoehn and Yahr Scale stage less than 3, diagnosis within 3  years 
of screening, and without current or imminent disability requiring dopaminergic therapy other 
than a stable dosage  of an MAO -B inhibitor. Detailed inclusion and exclusion criteria are 
specified in the clinical protocol.  Participants will be recruite d from approximately 60  clinical 
sites located through the US . 
2.4 Participant Flow  
After providing informed consent, participants will complete a sequence of three screening visits . 
At Screening Visit 1 (SC1), participants will be screening for serum urate levels and urine pH to 
evaluate the highest yield eligibility criteria (serum urate ≤5.7 mg/dL ) and evaluate risk of serum 
urate elevation ( urine p H ≤5.0 or history of gout, ). For those subjects who pass SC1, most of the 
remaining screening procedures are conducted on a longer second screening visit (SC2) . If 
participants are  still eligible , then a dopamine transporter (DAT) ligand binding brain scan will 
be acquired at a local neur oimaging center  and read centrally to exclude participants classified as 
having a scan  without evidence of dop aminergic deficit (SWEDD) . 
Eligible participants will be randomized , complete a baseline visit, and initiate study drug. 
Participants will be seen  in-clinic at 3, 6, and 12 weeks and then quarterly to 24 months for study 
visits and collection of blood samples to measure trough serum urate. Following study drug 
discontinuation , participants  will be followed during a 3-month wash -out period with monthly 
telephone calls and a final in-clinic study visit  27 months after baseline . 
Detailed descriptions of study procedures and timing are specified in the clinical protocol.  A 
schematic of participant flow is given below.  
 

SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 7 of 34 
 2.5 Treatment Allocation  
Prior to the baseline visit, eligible participants  will be  randomly allocated in equal proportion s to 
one of two treatment groups, oral inosine titrated to achieve  trough serum urate in the range 7.1 
to 8.0 mg/dL  or placebo , according to a permuted -block randomization schedule, stratified by 
site. The randomization schedule was prepared by computer program by the unblinded study 
statistician s. 
2.6 Treatment Administration  
Study drug will be orally self -administered in capsules containing 500 mg of inosine (act ive 
drug) or lactose (placebo) . Participants  will take up to two capsules three times per day (i.e., up 
to 3.0 gm/day)  based on individualized  titration that aims to achieve trough serum urate in the 
range 7.1 to 8.0 mg/dL  in the active arm and equivalent dosage  adjustments in the placebo arm . 
Details of the titration algorithm are specified in the clinical protocol.  Note , the maximum study 
drug dos age was reduced from 3.0 to 2.0 gm/day beginning 24  Jan 2018 based on safety 
concerns over a higher than expec ted rate of kidney stones  with greatest incidence among 
participants on  study drug dos ages greater than 2.0 gm/day.  
2.7 Allocation Concealment  
The randomization schedule is known only by the unblinded study statistician s who generated 
the schedule and implement the titration algorithm  and a calibrated urine alkalinization pro cess 
and by the study drug distributor . Concealment of the true treatment allocation of specific 
participants is achieved  by use  of matched  active and placebo capsules,  matched titration 
schedules , and matched urine alkalinization rates . Clinical m embers of the Steering Committee, 
site investigators and other site staff, clinical coordination and data management staff , the 
medical monitor, and all participants are blinded to particip ant treatment allocations. The Data 
and Safety Monitoring Board (DSMB ) members are provided treatment -specific information  in 
order to monitor the trial but such infor mation is masked by use of coded values to identify the 
treatment groups . The DSMB  may request the true treatment identities.  
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 8 of 34 
 2.8 Schedule of Assessments  
 

SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 9 of 34 
 3. Statistical Design  
3.1 Primary Outcome  
Our choice  of rate of change in MDS -UPDRS I -III total score as our primary efficacy measure is 
based on an interest in an outcome that can be evaluated within 2 years and an interest in a 
patient -reported outcome. Moreover, our preliminary data from the SURE -PD tria l (NCT 
[STUDY_ID_REMOVED] ) showed dosage -dependent efficacy of serum urate elevation for 24 -month 
change in UPDRS I -III total score. Anticipating that recruitment will require 18 months, 
evaluations of the primary outcome needs to be completed in 2 to 2.5 years in order to launch, 
implement, and  publish results from the trial within a 5 -year grant period.  
Assessing change in MDS -UPDRS or other measures of motor symptoms among initially de 
novo PD patients becomes more complex as subjects begin initiating dopaminergic therapy, with 
roughly two -thirds expected to have initiated dopaminergic therapy by 2 years in the placebo 
group. We feel that assessing motor symptoms when not on dopaminergic therapy best reflects 
the efficacy of the intervention under study, whereas evaluation in the OFF condition  after 
dopaminergic therapy has already been initiated is burdensome to subjects and unreliable due to 
incomplete and variable wash -out. Evaluating motor symptoms in the ON condition is prone to 
bias due to adjustment of dopaminergic therapy to achieve a p re-targeted level of symptoms. We 
propose instead to analyze MDS -UPDRS measurements made prior to initiating dopaminergic 
therapy, considering use of such treatments a censoring event that precludes observation of 
future untreated MDS -UPDRS scores. While d elaying progression over only 2 years provides 
less benefit to patients than we would ultimately wish to offer, we feel that a demonstration of 
delay over 2 years in the absence of symptomatic effects is an achievable result, one that could 
provide evidenc e of disease modification early in the clinical course, and may motivate a long -
term trial focused on functional and quality of life endpoints.  
3.2 Efficacy Outcomes  
Additional efficacy outcomes will include time to disability warranting dopaminergic therapy, 
the prescribed levodopa equivalent dos age (LEDD) , motor function as measured by MDS -
UPDRS part III, ambulation subset , and patient -reported sections (IB and II), striatal DAT 
binding by DaTscanTM, cognition as measured by MoCA, mood as measured by Neuro -QOL 
Depression , quality of life as measured by PDQ -39, and functional disability as measured by 
modified Schwab and England.  Measures of parkinsonian symptoms assessed by the MDS -
UPDRS will be analyzed in two ways: (a) excluding  assessments completed  after initia tion of 
dopaminergic medication , and (b) adjusting for time -dependent LEDD.  
3.3 Safety  Outcomes  
Safety of oral inosine titrated to achieve  trough serum urate in the range  7.1 to 8.0 mg/dL will be 
evaluated by comparing active vs. placebo treatment groups with respect to overall adverse event 
(AE) and serious adverse event ( SAE ) rate, time to first SAE, and proportions of subjects 
experiencing (a) each type of AE, classified by Me dical Dictionary for Regulatory Activities 
(MedDRA) preferred term and system organ class, (b) clinically -significant abnormal labs, and 
(c) clinically significant abnormal vital signs, including orthostatic hypotension defined as 
positional dizziness or o ther clinical symptoms of orthostatic hypotension or a drop in systolic 
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 10 of 34 
 and diastolic blood pressures of 20 mm Hg and 10 mg Hg or more, respectively, when moving 
from a supine to a standing position.  
3.4 Tolerability  
Tolerance of treatment by an individual participant  will be defined as remaining on -study and on 
his/her  assigned treatment without one or more AE-associated dosage  reductions lasting more 
than 4 weeks cumulative. Tolerability of oral inosine titrated to achieve trough serum urate in the 
range 7.1 to 8.0 mg/dL  will be defined as the proportion of all participants  in the active arm  who 
are tolerant of the treatment at 12 weeks (short -term) , 12 months  (medium -term),  and 24 months 
(long -term). Oral inosine titrated to achieve trough serum urate in the range 7.1 to 8.0 mg/dL  will 
be declared tolerable for a given dura tion of treatment if the proportion who are tolerant is 
significantly greater than 50%.  
3.5 Symptomatic Effect s 
Symptomatic effects will be estimated by changes in motor symptoms (a) during the first 3 
months of wash -in at the start of period 1 , and (b) during the 3 -month wash -out during  period 2  
or at the end of study drug exposure, if earlier . 
3.6 Two -period Evaluations  
Analysis of the persistence of benefit after the 3 -month wash -out of period 2 among subjects 
randomized to active treatment during period 1 permits an evaluation of disease -modifying effect 
of serum urate elevation. Not all measures are amenable to two -period evaluation because of the 
censoring effect of initiation of dopaminergic therapy. In particular, with only one -third of 
subjects expected to have not initiated dopaminergic therapy at the end of period 1, few data on 
uncensored MDS -UPDRS trajectories d uring wash -out will be available and subjects 
contributing th ose data are a non -random subset of slow progressors. For LEDD -adjusted 
analysis of MDS -UPDRS and other measures that are equally evaluable at the end of both 
periods, a three -part test of signif icantly slower worsening during period 1, non -inferior rates of 
worsening during period 2, and a significant net benefit at the end of period 2 would provide 
evidence of disease modification if all three evaluations were favorable.  
3.7 Effect Size  for Primary Outcome  
The effect size for determining power is based on estimates of the minimum clinically important 
difference (MCID) for changes in MDS -UPDRS I -III total scores and on the previously observed 
association between baseline serum urate level s and the rate of change in UPDRS I -III total 
scores in the DATATOP, PRECEPT, and SURE -PD trials.  
Hauser et al.1 report that placebo -treated subjects who reported being minimally worse over 26 
weeks on a global impression of change assessment experienced an average increase in UPDRS 
I-III total scores of 4.9 units. Given our expectation that elevated serum urate wil l delay 
progression, not improve symptoms, a MCID related to minimal worsening among placebo 
subjects seems most appropriate in this context. Based on estimates by Goetz and colleagues2-5 
for PD patients with mild symptoms (Hoehn and Yahr stage I/II), MDS -UPDRS I -III total scores 
are roughly 30% larger than UPDRS I -III total scores (2.5x for 16 questions in Part 1, 1.1x for 52 
questions in Part II, and 1.2x for 108 questions in Part III, yielding a weighted conversion of 
1.29x), implying a MCID of 6.3 MDS -UPDRS I -III total score units.  
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 11 of 34 
 We expect to enroll subjects with mean baseline serum urate of approximately 4.5 mg/dL based 
on data from SURE -PD and then raise levels in the active arm 3 mg/dL on average at trough 
sampling. A 3 mg/dL difference in baseline  serum urate predicted 8.1 and 2.1 unit per year 
differences in UPDRS I -III total score slopes in the DATATOP6 and PRECEPT7 trials. In the 
SURE -PD trial8, subjects randomized to moderate serum urate elevation (7 to 8 mg/dL at random 
sampling) progressed 1. 1 unit / year slower than placebo arm subjects with wide confidence 
bounds (95% CI 4.8 units / year slower to 2.8 units / year faster). Note that this estimate from 
SURE -PD (see protocol Fig. 7D) is conservative relative to an alternative model for the eff ect of 
serum urate elevation (see protocol Fig. 7C). A random -effects meta -analysis of results from the 
three studies yields a weighted estimate of 4.5 units slower progression in UPDRS I -III total 
score over 2 years among patients with higher serum urate levels.   
We propose that 6.3 units over two years or a 
difference in slopes of 3.15 units per year is a 
reasonable minimum clinically important 
difference (MCID) in MDS -UPDRS I -III total 
scores, equal to a MCID of 4.9 units on the scale of 
UPDRS I -III total scores. This would correspond 
to a reduction of 20% of the expected placebo rate 
based on a random e ffects meta -analysis ( Fig. 1 
[from protocol Fig. 1 3]) of the mean rates of 
decline in UPDRS I -III total scores among de novo 
PD patients with baseline serum urate levels below 
5.9 mg/dL in the DATATOP9,10, PRECEPT11, and 
SURE -PD8 cohorts. Changes in UPDRS I-III total 
scores were analyzed using random -slope mixed 
models censoring follow -up when dopaminergic 
therapy was initiated. The weighted mean estimate 
was 0.98 points / month or 23.5 points over 2 years 
with substantial heterogeneity in the estimate 
amon g studies (see Fig. 1).  
3.8 Sample Size  
Power for the primary outcome of rate of change in MDS -UPDRS I -III total score is based on a 
random slopes model with shared baseline. The model will include fixed effects of time, 
treatment x time, sex, sex x time, an i ndicator of baseline MAO -B inhibitor use, and baseline 
MAO -B inhibitor use x time and random site - and subject -specific intercepts and slopes, each 
with unstructured covariance. MDS -UPDRS assessments completed after a subject has initiated 
dopaminergic the rapy will be censored.  
Based on applying the same primary analysis model to data from SURE -PD, the following 
variance components were estimated for UPDRS I -III total scores: site -level variance (intercept 
= 9.75, slope = 0.0123 / month, covariance = -0.346), subject -level variance (intercept = 77.4, 
slope = 0.230 / month, covariance =2.87), and residual variance = 13.9. We assume that 70% of 
subjects will initiate dopaminergic therapy based on experience in SURE -PD plus up to 8% 
additional lost to follow -up prior to initiating dopaminergic therapy. With the planned schedule 
for MDS -UPDRS assessments (screening, baseline, 3 weeks, 6 weeks, 12 weeks, and then 
Figure 1. Meta -analysis of the rate of UPDRS 
change in early PD subjects with lower serum 
urate.  Early, largely untreated PD subjects with a serum urate of <5.9 mg/dL at baseline 
from DATATOP (n=155; double -placebo 
only), PRECEPT (n=446) and SU RE-PD 
(n=25; placebo only) were followed for up to 
two years. The overall UPDRS rate was obtained by weighting each estimate by the inverse of its standard error. 

SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 12 of 34 
 quarterly through 24 months), the variance and censoring estimates above imply an effective 
standard deviation for UPDRS I -III total score slopes of 0.587 units / month or 0.758 units / 
month on the scale of MDS -UPDRS I -III total scores.12 
Given a standard deviation of 0.76 units / month, a final two -sided test at alpha = 0.046 allowing 
conservatively for  two interim analyses at alpha = 0.001 each, the study would have 80% power 
with n = 270 subjects randomized 1:1 to placebo or urate elevation if the true effect of treatment 
were to reduce the rate of increase in MDS -UPDRS I -III total score by 6.3 points over 2 years.  
This estimate of power is robust to variable sex-specific enrollment rates and treatment efficacy 
as long as the average effect of treatment across sexes in the ratio enrolled is 6.3 points over 2 
years (Fig. 2A). If urate elevation reduces t he average rate of progression by 6.3 points over 2 
years only among male or female participants and the other sex experiences less benefit, power 
would be lower (Fig. 2B). This is unavoidable if a large proportion of the enrolled population 
accrues less b enefit from the intervention. Conversely, power would be greater than 80% if one 
sex experiences a benefit greater than 6.3 points over 2 years and the other sex experiences at 
least that large a benefit.  
 
Figure 2. (A) Power for the primary aim across a range of sex-specific treatment responses, all 
cases with the average treatment response across sexes equal to the MCID of 6.3 points over 2 
years. Note that equal prevalence of male (M) and female (F) parti cipants is plotted, but the 
power curve for other prevalence ratios are so similar as to be indistinguishable at this scale. (B) 
Power for the primary aim when the effect of treatment on one sex is equal to the MCID and the 
effect on the alternate sex varies from 50% to 150% of MCID for a range of different prevalence 
ratios.  
3.9 Power for Secondary Outcomes  
The trial will have an 80% probability of observing at least one instance of any class of adverse 
event expected to occur in at least 1.2% of individuals receiving inosine. The trial will have 80% 
power to detect increased risk of any class of adverse even t among subjects receiving inosine if 
the true risk is two -fold higher and the expected proportion among placebo subjects is at least 
14% or if the true risk if four -fold higher and the expected proportion among placebo subjects is 
at least 3.4%. The trial  has 80% probability of declaring serum urate elevation tolerable if the 
true proportion tolerant under the definition given in Sec. 3.4 at 12 weeks , 12 months,  and 24 
months is at least 62%.  
B A 
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 13 of 34 
 The estimated SE for symptomatic effects on UPDRS I -III total sc ores during wash -in between 
the moderate elevation and placebo arms in the SURE -PD trial was 0.53 units / month. With n = 
25 subjects per treatment group in SURE -PD, the expected SE for estimating symptomatic 
effects in this trial will be roughly sqrt (25/ 135) * 0.53 = 0.23 units / month. With that SE, the 
trial would have 80% power to detect symptomatic effects on the order of a difference in slopes 
during wash -in or wash -out of 0.65 units/month.  
The Kaplan -Meier product -limit estimate from the SURE -PD tr ial of the proportion of placebo 
subjects requiring dopaminergic therapy by 24 months was 62%. Assuming constant hazard at 
the same rate among placebo subjects in this trial during period 1 (0 to 24 months) and 8% loss 
to follow -up prior to determining nee d for dopaminergic therapy, the trial will have 80% power 
to detect a hazard ratio of 0.62. Extrapolating to 27 months, we expect a total of 67% of placebo 
arm subjects to have disability warranting dopaminergic therapy at the end of period 2 (24 to 27 
months). The study would have 80% power to detect a difference in the proportion of subjects 
with disability warranting dopaminergic therapy if 50% or fewer of active arm subjects have 
progressed by the end of the trial.  
Given preliminary data from SURE -PD o n the variance components from random -slope models 
for MoCA after Rasch score conversion, GDS -15, and S&E ADL, the effective standard 
deviations (in points per month) for these measures given our planned follow -up schedule are 
0.038, 0.097, and 0.31, respe ctively. Weaver et al.13 report an among -person standard deviation 
for PDQ -39 at 24 months after deep brain stimulation of 14.2 to 15.3. Assuming conservatively 
no within -person covariance, that would imply a standard deviation for 24 -month change of 
appro ximately 30. Given these estimates, the trial will have 80% power to detect 2 -year 
treatment differences on these outcomes as small as 0.31, 0.80, 2.5, and 10.3, respectively.  
4. Baseline Characteristics , Study Endpoints , and Final Disposition  
4.1 Baseline Charac teristics  
Each analysis sample will be summarized overall and by treatment group for the following 
characteristics: randomization site; age, sex, race, ethnicity, time since symptom onset,  time 
since PD diagnosis, modified Hoehn and Yahr score, resting tremor, use of an MAO -B inhibitor, 
serum urate, MDS -UPDRS  scores , NeuroQoL module scores , years of education, MMSE, 
MOCA score , PDQ -39 score , modified Schwab and England ADL score, smoking history, 
caffeine consumption,  sense of smell,  RBD history,  vigorous physical activity, serum urate,  DAT 
ligand uptake, BMI, supine s ystolic and diastolic blood pressure , and orthostatic hypotension . 
4.2 Expectancy  and Treatment Preference  
Measures of expectancy will be obtained once at baseline by self -report . Partic ipants will be 
asked their  expectati ons of benefit from placebo and oral inosine treatment and their relative 
preference for placebo vs. oral inosine.  
4.3 Efficacy Endpoints  
The primary outcome of the trial is rate of change in MDS -UPDRS I -III total score over 24 
months estimated in the ITT sample from a shared -baseline, random -slopes mixed model, 
censoring follow -up of subjects after ini tiation of dopaminergic therapy . 
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 14 of 34 
 Second ary efficacy endpoints include the following : 
• MDS -UPDRS scores: Parts I, II, III, IV, ambulation, and patient -reported sections (Parts IB 
and II) , 
• Striatal DAT binding by DaTscanTM,  
• Neuro -QOL module scores: Lower Extremity Function, Upper Extremity Function, Anxiety, 
Depression, Positive Affect and Well -being , Cognit ive Function , Fatigue, Sleep Disturbance, 
Emotional and Behavioral Dyscontrol, Communication , Ability to Participate in Social Roles 
and Activities , Stigma, and Satisfaction with Social Roles and Activities,  
• Montreal Cognitive Assessment (MoCA)  score  to assess cognition ,  
• Parkinson’s Disease Questionnaire - 39 item version (PDQ -39) score  to assess quality of life ,  
• Modified Schwab and Engl and ADL score  to assess functional disability ,  
• Orthostatic vital signs: supine to standing change in systolic  blood pressure,  diastolic blood 
pressure , and heart rate; orthostatic hy potension, and  
• Medical intervention: levodopa equivalent daily dosage , disability warranting initiation of 
dopaminergic therapy . 
Explor atory efficacy endpoints  include: REM sleep behavior disorder (RBD) symptom s and 
symptom  severity, quantitative measures derived from tasks completed using the Smart 4SURE 
implementation of the mPower smartphone app. 
4.4 Intervention and Pharmacodynamic Endpoint s  
Intervention intensity will be assessed by capsule count. Pharmacodynamic effect  of oral inosine 
on serum urate will be assessed by direct measurement. Effects of oral inosine on urate excretion 
will be assessed by comparing measurements of serum urate and 24 -hour urine urate excretion.  
4.5 Safety Endpoints  
The following safety endpoints will be evaluated:  
• Overall TEAE and serious TEAE incidence rate,  
• Time to first serious TEAE ,  
• Proportion of participants experiencing  and number of unique events of each type of  TEAE  
and serious TEAE classified by MedDRA system organ class and preferred term ,  
• Proportion of participants experiencing  and number of unique events of each type of  TEAE 
within the group of events specified as of  special interest,  
• Proportion of participants experiencing and number of unique event s of TEAEs classified by 
seriousness, severity, relatedness to study drug, action taken with study drug, and outcome , 
summarized across all  MedDRA term s,  
• Mean change from baseline in  safety labs: complete blood count , leukocyte differential, 
electrolytes, renal panel, liver function tests, lipid profile, thyroid stimulating hormone , and 
urina lysis of spot and 24 -hr samples,  
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 15 of 34 
 • Mean change from baseline in blood pressure (supine and standing), heart rate (supine and 
standing), orthostasis  (change from supine to standing),  and body weigh t,  
• Mean change from baseline in  ECG  parameters,  
Reported proportions will use as their denominato r all participants in the Safety and Tolerability 
sample (see Section 5.2 below) . 
4.6 Tolerability Endpoint  
Tolerance of treatment by an individual participant will be defined as remaining on -study and on 
his/he r assigned treatment without one or more AE-associated dosage  reductions lasting more 
than 4 weeks cumulative.   Tolerance will only be assessed through  24 Oct 2018, the day before  
clinical sites were notified of early study closeout , as discontinuation of study drug after that date 
may reflect a change in participants' or investigators' equipoise.  Tolerability of oral inosine 
titrated to achieve trough serum urate in the range 7.1 to 8.0 mg/dL will be defined as the 
proportion of al l participants in the active arm who are tolerant of the treatment at 12 weeks 
(short -term), 12 months (medium -term), and 24 months (long -term). Oral inosine titrated to 
achieve trough serum urate in the range 7.1 to 8.0 mg/dL will be declared tolerable fo r a given 
duration of treatment if the proportion who are tolerant is significantly greater than 50%.  
4.7 Blinding  
The presumed treatment group to which a participant was assigned, a respondent 's confidence in 
that presumption , and the reason for that presumpt ion will be collected from participants, site 
investigators, and coordinators at the 6 week visit and at the end of treatment.  The proportion 
guessing correctly or incorrectly and the odds ratio of guessing the true  treatment vs. the wrong 
treatment will b e evaluated for each class of respondent , both overall and among the subset of 
respondents who assert being at least somewhat sure of their guess . 
4.8 Final Disposition  
The proportion of participants who permanently discontinue study drug, discontinue clinic v isits, 
fully withdraw consent, or are lost to follow -up prior to planned study completionwill be 
summarized overall and by treatment group  for each period, both overall and stratified by 
occurrence before vs. on or after 25 Oct 2018 , when clinical sites were notified of early study 
closeout . The probability that each participant has idiopathic PD based on the site investigator's 
primary diagnostic assessment at the participant's final visit  will be summarized overall and by 
treatment group.  
5. Measurement De finitions  
5.1 Movement Disorders Society Unified PD Rating Scale (MDS -UPDRS)  
The MDS -UPDRS138 will serve as the primary outcome variable of the study and will be 
conducted at all standard visits beginning with SC2. The MDS -UPDRS was designed by 
movement disorders experts to address weaknesses of the original UPDRS (e.g., by adding 
questions on constipation and sialorrhea) while  preserving its overall format.  
The instrument is  divided into four parts:  
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 16 of 34 
 • Part I (non -motor experiences of daily living) , compri sing 
o Part IA concerning behaviors that are assessed by the Site Investigator with all 
pertinent information from participants  and caregivers  
o Part IB that is completed by the participant  with or without the aid of the 
caregiver, but independently of the Sit e Investigator.  
• Part II (motor experiences of daily living) , designed to be a self -administered 
questionnaire like Part IB, but similarly can be reviewed by the Site Investigator to 
ensure completeness and clarity.  
• Part III (motor examination) has instruct ions for the rater to give or demonstrate to the 
participant ; it is completed by the clinician rater.  
• Part IV (motor complications)  with instructions for the rater and also instructions to be 
read to the participant . This part integrates participant -derive d information with the rater's 
clinical observations and judgments and is completed by the rater.  
The full MDS -UPDRS has sixty -five items, each assessed on a 5-point Likert scale  ranging from 
0 to 4 with 0=none, 1=slight, 2=mild, 3=moderate, 4=severe. Total scores for Parts I, II, III, and 
IV and for Parts I through III collectively are calculated as simple sums of component items with 
mean imputation  by Part if no more than 1, 2, 7, or 0 items is missing for Parts I through IV, 
respectively.16 Two additional summary scores will also be constructed: ambulatory capacity 
(sum of 5 MDS -UPDRS questions: walking  and balance [question 2.12], freezing  [q. 2.13], gait 
[q. 3.10], freezing of gait [q. 3.11], and postural stability  [q. 3.12] ) and patient -reported 
symptoms (sum of Parts IB and II) . Higher scores imply worse symptoms.  
Participants  will self -administer Parts IB and II  and will review responses for accuracy and 
clarity with the Site Investigator  or Coordinator. Parts IA, III and IV will be condu cted by the 
Site Investigator . Parts I, II, and III will be conducted at study visits as indicated on the Schedule 
of Activities (Sec. 2.8). Part IV will be conducted at visits where MDS -UPDRS Parts I -III are 
conducted but only for participants  who have st arted on symptomatic therapy after the Baseline 
visit.  
Use of MDS -UPDRS is responsive to core instrument recommendations for the Quality of Life 
subdomain of the NINDS CDEs for PD  and to FDA guidance encouraging use of patient -
reported outcomes (PROs) as a  substantial portion of the responses are patient -reported. The 
same Site Investigator should assess all subjects on parts IA and III of the MDS -UPDRS at all 
study visits.  
5.2 Modified Schwab & England Activities of Daily Living Scale  
The Schwab & England sca le181,182 is a Site Investigator and subject assessment of the subject’s 
level of independence. The subject will be scored on a percentage scale reflective of his/her 
ability to perform acts of daily living. Printed scores with associated descriptors range  from 0% 
to 100% in increments of 5%, with higher percentages associated with more independence. A 
score of 0% implies “vegetative functions such as swallowing, bladder and bowel functions are 
not functioning; bedridden” . A score of 100% implies  “subject has full ability and is completely 
independen t; essentially normal” . This joint participant /Site Investigator assessment will be 
conducted periodically at the visits indicated in Sec. 2.8. 
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 17 of 34 
 5.3 Parkinson’s Disease Questionnaire - 39 item version (PDQ -39) scale  
The PDQ -39 asks 39 questions organized over eight domains (scales): mobility (10 items), 
activities of daily living (6 items), emotional well -being (6 items), stigma (4 items), social 
support (3 items), cognition (4 items), communication (3 items ), and bodily discomfort (3 items). 
Each item has five possible ordinal responses, from never to always, depending on frequenc y of 
the symptom over the prece ding month. The eight scales’ scores are generated by Likert’s 
method of summated ratings and then transformed to a single figure  that ranges from 0 to 100. 
Higher scores are associated with more symptoms. The PDQ -39 is the most widely used health 
related -QoL instrument in PD, and is considered to have generally good psychometric properties 
and content validity.183,184 Use of PDQ -39 is responsive to core instrument recommendations for 
the Quality of Life subdomain of the NINDS CDEs for PD, and to FDA guidance encouraging 
use of PROs. This assessment will be collected from subjects periodically at the vis its indicated 
in Sec. 2.8. 
5.4 Modified Hoehn and Yahr Scale  
The Modified Hoehn and Yahr Scale181, 185 is a 6 -level PD staging instrument of motor 
manifestations and disability. It is a n ordinal scale, s cored by the Site Investigator. Scores range 
from 0 to 5 with higher scores associated with more motor symptoms and disability.  Stage 0 is 
“no signs of disease”, stage 1 is “unilateral disease’, stage 1.5 is “unilateral disease with axial 
involvement”, stage 2 is “bilateral disease, without balance impairment”, stage 2.5 is “bilateral 
disease, with recovery on the pull test”, stage 3 is “mild to moderate bilateral disease; needs 
assistance to prevent falling on pull test”, stage 4 is “severe disability, but still able to walk or 
stand unassisted” and stage 5 is “ wheelchair bou nd or bedridden unless aided.” This Site 
Investigator assessment will be conducted periodically at  the visits indicated in Sec. 2.8.  
5.5 Assess Need for Dopaminergic Therapy  
At each visit beginning with Baseline Visit, the Site Investigator will assess the subject’s need 
for dopaminergic therapy. (See Sec. 5.3.3.1 for definition of dopaminergic therapy.) A 
questionnaire will be used to facilitate the Site Investigator’s decision. As in the DATATOP9,10 
and PRECEPT11 trials, this will be based on PD  disability posing a threat to the subject’s current 
occupational status, current abilities (potential capacities) related to occupational matters, to 
handle routine personal finances and domestic responsibilities, and activities of daily living.  
Subjects  who are judged to require dopaminergic therapy at Baseline or are thought likely to 
need therapy within the 3 months after Baseline, will be excluded from participation in this 
study.  Subjects who are judged to require dopaminergic therapy after starting study drug will 
continue in the study after anti -parkinsonian  therapy is instituted.  
5.6 Mini -Mental State Examination (MMSE)  
The Mini -Mental State Examination186 is a 30 -point ordinal sc ale that is widely used for the 
evaluation of degenerative dementia in patients with a variety of neurologic and psychiatric 
disorders, and is designated an NINDS CDE for PD. The MMSE includes 11 questions which 
evaluate orientation (10 points), immediate recall (3 points), attention (5 points), delayed recall 
(3 points), naming (2 points), repetition (1 point), 3 -stage command (3 points), reading (1 point), 
copying (1 point) and writing (1 point). The test is referred to as “mini” because it focuses only 
on the cognitive aspects of mental functions and does not include questions related to mood, 
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 18 of 34 
 abnormal mental experiences, or the form of thinking. The total score ranges from 0 to 30, with 
higher scores signifying better cognition. A total score of 23 or le ss is associated with varying 
severities of cognitive impairment.  
Subjects will complete the MMSE at the Screening Visit 2. Participants  with an MMSE score 
less than 25 will be excluded from participation in the study.   
5.7 Montreal Cognitive Assessment (MoC A) 
The MoCA (Nasreddine et al. 2005) consists of 8 clinician -administered cognitive tasks designed 
to screen for mild cognitive impairment. The MoCA assesses attention and concentration, 
executive functions, memory, language, visuoconstructional skills, co nceptual thinking, 
calculations, and orientation.  The MoCA was developed to be more sensitive than the MMSE to 
patients presentin g with mild cognitive complaint  and may be less prone to a ceiling effect 
(Zadikoff  et al. 2008) . One point is awarded for corr ect completion of each item of the 
visuospatial/executive function task (5 items), naming task (3 items), digit vigilance and tapping 
items of the attention task (3 items), the sentence repetition items of the language task (2 items), 
abstraction task (2 i tems), delayed recall task (5 items), and orientation task (6 items). One point 
is awarded for naming 11 or more words during the fluency item of the language task. Zero 
(none correct) to 3 (4 or more correct) points are awarded based on the number of corr ect 
subtractions by 7 starting at 100 in the attention task. One point is awarded if the participant has 
12 years or less of education unless the score is already 30. Scores for each task are summed for 
a total score (range 0 to 30) with higher scores indi cating greater cognitive capacity.  The MoCA 
will be administered by Site Investigators at Baseline, Week 12, Month 12, Month 24 and Month 
27 or the Discontinuation of In -person Follow -up Visit for subjects unwilling to continue in -
person visits.  
5.8 Quality of  Life in Neurological Disorders  (Neuro -QOL)  
Neuro -QOL is a set of patient -reported outcome (PRO) measures that assess health -related 
quality of life (HRQ oL) of people with neurological disorders.190,191 It facilitates comparisons 
between diseases and withi n individual patients over time. Developed through a collaborative 
NINDS -sponsored research initiative, Neuro -QOL is an NINDS CDE and has been validated in 
multiple patient populations including PD.190,192 It comprises 17 domains of HRQL covering 
physical,  psychological and social health. It has 13 item banks, 3 item pools and 1 stand -alone 
scale. There are short forms for each item bank which each form containing 8 to 9 items. 
Domains tested include anxiety, cognitive function, communication, depression, e motional and 
behavioral dyscontrol, fatigue, lower extremity function - mobility, positive affect and well -
being, stigma, upper extremity function - fine motor and ADL, sleep disturbance, satisfaction 
with social roles and activities, and ability to particip ate in social roles and activities. Higher raw 
scores are associated with more of the concept being measured. In a PD population, Neuro -QoL 
measures including its short forms have demonstrated high internal consistency, with acceptable 
test-retest reliabil ity and support for convergent validity with PD specific measures including 
PDQ -39 and MDS -UPDRS.190 An instrument comprising multiple short form domains will be 
employed before and after the study drug treatment period (at SC2 and SV) while the depression  
domain will be employed on its own at additional visits during the treatment period, as indicated 
in Sec. 6.3. 
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 19 of 34 
 5.9 Initiation of Dopaminergic Therapy  
For the purposes of this trial, t he date at which a participant initiates dopaminergic therapy will 
be calcul ated as the first day that the participant either (a) initiates use of one of the following 
medications  as label ed in the WHO Drug Dictionary : amantadine , pramipexole , ropinirole , 
rotigotine , sinemet , trihexyphenidyl , benztropine, rasagiline , selegiline , safinamide, or levodopa  
at a LEDD greater than 2 mg /day, or (b) increases the LEDD  of one of the following medications 
over the dosage  taken at baseline  by more than 2 mg /day: rasagiline , selegiline , safinamide . 
5.10 Primary Diagnosis Assessment  
The Primary Dia gnosis form captures, in the Site Investigator’s opinion, a current percentile 
probability the subject has idiopathic Parkinson disease based on available information. Ranges 
include: 90 -100%; 50 -89%, 10 -49% and 0 -9%. In addition the Site Investigator sele cts the most 
likely primary diagnosis from a listing that includes idiopathic PD, many other neurological 
disorders, and the option of no neurological disorder. To correlate with the MDS -UPDRS, this 
percentile probability and most likely diagnosis will be captured at Month 27 or the 
Discontinuation of In -person Follow -up Visit for subjects unwilling  to continue in -person visits.  
5.11 Diagnostic Features Assessment  
The Diagnostic Features form is a companion to the Primary Diagnosis form. It is a review by 
the Site Investigator of factors that do and do not suggest a di agnosis of Parkinson disease. This 
assessment is completed at Month 27 or the Discontinuation of In -person Follow -up Visit for 
subjects unwillin g to continue in -person visits.  
5.12 Dopamine Transporter  (DAT) Neuroimaging  
A radionuclide -labeled dopamine transporter (DAT) ligand, and specifically DaTscanTM (123I-
ioflupane injection), is approved by the FDA for striatal DAT visualization using single photon 
emission computed tomography (SPECT) brain imaging to assist in the evaluation of adult 
patients with suspected parkinsonian syndromes. DaTscanTM is approved to help differentiate 
essential tremor from tremor due to parkinsonian syndromes  (including idiopathic PD, multiple 
system atrophy and progre ssive supranuclear palsy) and not for the diagnosis of PD among 
parkinsonian syndromes. Nevertheless, DAT brain scans (using any of several radioligands) in 
clinical research have consistently identified a small but substantial (~10%) portion of subjects 
who are enrolled in clinical trials based on an expert clinician diagnosis of probable early PD but 
who turn out to be unlikely to have PD.30,140,143,145 -147 
DAT scans will be performed prior to the baseline visit, and will generally be conducted as the 
final screening evaluation (DS1) at a certified neuroimaging center at or near the clinical site. A 
determination of whether DaTscanTM imaging supports a diagnosis of PD and therefore study 
eligibility will be made by the study imaging core. Its experienced n uclear medicine specialists 
(trained in the visual read method appropriate for D aTscanTM) will perform the qualitative 
eligibility assessment. Each scan will be assessed independently by at least two readers  as 
described in the Imaging Core Charter .  
An ad ditional follow -up DaTscanTM imaging study (DS2) will be performed one to two months 
following the final study clinic visit (V10 , or its equivalent ), and before the final safety visit 
(SV), for active SURE -PD3 subjects who have consented to participate in a serial DAT scan 
substudy, who have been on study drug through at least the 1 -year visit (V06), and who are not 
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 20 of 34 
 using or expected to use any of the following medications within 90 days prior to DS2:  
modafinil, armodafinil, metoclopramide, alpha -methyldopa , methylphenidate, reserpine, or 
amphetamine derivative.  The substudy will quantify changes in DAT binding between the pre -
study drug exposure and post -study drug exposure timepoints.  
5.13 Orthostasis  
Orthostatic hypotension will be defined as a maximum decrease of 20 mm Hg or greater in 
systolic blood pressure (SBP) or a maximum decrease of 10 mm Hg or greater in diastolic blood 
pressure (DBP) when moving from a supine to a standing position, with measurements 
completed 1 min and 3 min after standing.  
5.14 Levodopa Equivalent Daily Dos age 
The levodopa equivalent daily dos age (LEDD) will be calculated using data from the 
concomitant medications log. The conversion from dopamergic drugs other than carbidopa -
levodopa will follow the recommendations by Tomlinson e t al. (2010) with the following 
additions for anti-cholinergic  medication s and more recently approved drugs.  
• Trihexyphenidyl (Artane™) will be converted at 25 mg levodopa equivalent per mg 
trihexyphenidyl  based on equivalent symptomatic effect of 8 mg/day trihexyphenidyl and 
200 mg/day amantadine reported in Park es et al. (1974);  
• Benztropine (Cogentin™) will be converted at 50 mg levodopa equivalent per mg 
benztropine based on  the ratio of the recommended range of total daily dosages for treating 
Parkinson disease patients between benztropine and trihexyphenidyl ; 
• Extended release formations of carbidopa -levodopa (Rytary™) will be converted at 60% of 
their levodopa content based on mean post -baseline daily dosages reported in Hauser et al. 
(2013);  
• Extended re lease formations of ropinorole (RequipXL™) will be converted at 20 mg 
levodopa equivalent per mg ropinirole  based on equivalent maximum recommended daily 
dosage;  
• Safinamide ( Xadago ™) will be converted at 2 mg levodopa equivalent per mg safinamide 
based on a retrospective study by Mancini et al. (2018) . 
The full calculation is as follows:  
1. At each time any oral levodopa is taken per day, c alculate the immediate release 
levodopa  (e.g., Sinemet, Parcopa) dosage (mg) based on the number of tablets taken per 
dose and the dosage of levodopa in each tablet  
2. At each time any oral levodopa is taken per day, c alculate the control led release levodopa 
(e.g., Sinemet CR) dosage (mg) and multiply by 0.7 5 to account  for loss of bioavailability  
3. At each time any oral levodopa is taken per day, c alculate the extended  release levodopa 
(e.g., Rytary) dosage (mg) and multiply by 0. 60 to account  for loss of bioavailability  
4. At each time any oral levodopa is taken per day, calculate the total daily oral levodopa 
dosage by summing together the oral levodopa dosage from immediate release, controlled 
release, and extended release formulations (quantities 1 through 3)  
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 21 of 34 
 5. At each time any oral levodopa is taken per day, i f entacapone but not tolcapone is taken 
at the same time, either sepa rately or as a c ombination drug  (e.g., Stalevo) , then multiply 
the total  levodopa dosage at that time (quantity 4) by 0.33  
6. At each time any oral levodopa is taken per day, i f tolcapone (e.g., Tasmar) is taken at the 
same time , then multiply the total  levod opa dosage at that time (quantity 4 ) by 0. 50 
7. Calculated the COMT -adjusted total daily levodopa equivalent dosage associated with 
oral levodopa as the sum over all time points of quantities 4 through 6  
8. If enteral levodopa  is taken  without any COMT inhibitor , then multiply the total enteral 
levodopa  (e.g., Duopa) daily dosage (mg)  by 1.11  
9. If enteral levodopa  is taken  with e ntacapone but not tolcapone , then multiply the total 
daily enteral levodopa  dosage (mg)  by 1. 48 
10. If enteral levodopa  is taken  with tolcapon e, then multiply the total daily enteral levodopa  
dosage (mg)  by 1. 67 
11. If immediate release or modified release pramipexole (e.g., Mirapex) is taken, multiply 
the daily dosage (mg/day of the dihydrochloride monohydrate salt)  by 100  
12. If immediate release or e xtended release r opinirole  (e.g., Requip, Requip XL ) is taken, 
multiply the dosage (mg/day)  by 20  
13. If a rotigotine patch (e.g., Neupro) is used , multiply the dosage (mg/day)  by 30  
14. If oral s elegiline (e.g., E ldepryl ) is taken, multiply the dosage (mg/day)  by 10  
15. If sublingual s elegiline (e.g., Zelapar ) is taken, multiply the dosage (mg/day)  by 80  
16. If oral r asagiline (e.g., Azilect ) is taken, multiply the dosage (mg/day)  by 100  
17. If oral safinamide  (e.g.,  Xadago ) is taken, multiply the dosage (mg/day)  by 2 
18. If oral amantadine (e.g., Symmetrel ) is taken, multiply the dosage (mg/day)  by 1 
19. If an injection or infusion of a pomorphine (e.g., Apokyn) is taken, multiply the dosage 
(mg/day)  by 10  
20. If oral trihexyphenidyl  (e.g., Artane) is taken, multiply the dosage (mg/day ) by 25 
21. If oral benztropine  (e.g., Cogentin) is taken, multiply the dosage (mg/day)  by 50 
22. Calculate total LEDD as the sum of quantities 7 through 21. 
5.15 Blindedness Evaluation  
At week 6 and either month 24  (V10), V10 -equivalent visit due early study closure,  an 
Unscheduled Visit due to study drug discontinuation , or a Discontinuation of In -person Follow -
up Visit (whichever of the 4 visits comes first), the Site Investigator, Coordinator, and subject 
will complete a blindedness evaluation in which each is aske d to give his/her independent 
impression of the subject’s treatment assignment and the primary and secondary reasons for this 
opinion. Participants'  responses will not be available to the site Investigator or Coordinator when 
they make their assessments.  
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 22 of 34 
 5.16 Genetics   
DNA samples will be sequenced using whole genome sequencing (WGS) supported by the 
NIH’s Acceler ating Medicines Partnership for Parkinson’s Disease (AMP -
PD; https://www.nih.gov/research -training/accelerating -medicines -partnership -amp/parkinsons -
disease ) based on established methods (e.g, Allen  et al.  2016 ), with variants scored  under the 
AMP program 
(e.g, http://www.type2diabetesgenetics.org/variantSearch/variantSearchWF ; Butkiewicz et al. 
2018 ). The following single nucleotide polymorphisms ( SNPs ) or repeat polymorphisms may be 
investigated  amongst emerging genetic variants contributing to pro gression of PD across motor, 
non-motor and holistic  domains ( Iwaki et al. 2019 ), with simple additive , recessive, dominant, 
interactive, haplotypic, polygenic  or other models  to be determined  based on current 
understanding of genetic risk  determinants upon availability of WGS expected by ear ly 2020.  
Genetic predictors of PD progression that may be specific for urate -targeting inosine treatment, 
and those that are more likely generalized will be cons idered:  
• Potential predictors of PD progression, specific to urate/inosine intervention; e.g.:  
o rs1109303  (INPP5K ), stratif ying for TT vs G carriers (Nazeri et al. 2015 ) 
o s6855911 , rs7442295 , rs16890979  (SLC2A9 ; encoding urate transporte r gene  
Glut9 ), adjusting for and stratifying by a  composite score of proportional to the # 
of their minor alleles) ( Simon et al. 2014 ) 
o rs223 1142  (ABCG2  encoding urate transporte r gene ), stratifying for CC vs A 
carriers (Matsuo et al. 2015 ) 
• Potential predictors of PD progression, generalized; e.g.:  
o rs76904798 (near/5’ to LRRK2 ) (Iwaki et al. 2019 ) 
o D4S3481 ( SNCA -Rep1; complex repeat polymorphism upstream of SNCA )  (Ritz 
et al. 2012 ) 
o rs76763715  (GBA  N370S; but MAF 0.007) ( Davis et al. 2016 ) 
o rs9298897 and rs17710829 , alone and in a modeled interaction ( Latourelle et al. 
2017 ) 
o rs2230288  (GBA ), rs17649553  (MAPT ), apolipoprotein E4  (APOE 4), COMT 
val158met (COMT ) and BDNF val66met (BDNF ) alone and in additive model for 
cognitive progression outcomes ( Iwaki et al. 2019 ; Caspell -Garcia et al. 2017 ). 
5.17 Exploratory Assessments  
Three brief, self -administered questionnaires will be included t o explor e whether readily 
ascertained historical factors modify or otherwise interact with inosine effects.  
• REM Sleep Behavior Disorder (RBD) Single -Question  Screen (RBD1Q) – A single 
“yes-no” question on dream -enactment behaviour will be asked a t SC1, BL, and 3 mo, 12 
mo, 24 mo, and 27 mo visits.  
• PD Risk Factors Questionnaire  – A self -administered questionnaire assessing 
exposures and experiences linked to the risk of PD will be collected at BL. The 
questionnaire was developed by the PSG and deri ved from NINDS CDEs.  
• PD - Expectancy Questionnaire  – A self -administered questionnaire assessing 
expectations of study drug effect will be collected at BL.  
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 23 of 34 
 • Smart 4SURE assessments – A set of smartphone metrics of parkinsonian features 
adapted from the mPowe r app developed as a sub -study of SURE -PD3.  
6. Statistical Methodology  
6.1 General Considerations  
6.1.1  Statistical Software  
All statistical analyses will be performed using SAS (SAS Institute, NC, USA)  or R ( R 
Foundation for Statistical Computing , Vienna, Austria ).  
6.1.2  Summary Statistics  
Data will be summarized with respect to disposition, demographic s, pre-treatment 
characteristics, safety outcomes , tolerability, and efficacy outcomes . Summary statistics for 
continuous variables will include the number of subjects, the m ean, median, standard deviation, 
and range. For categorical data, summaries will include counts and percentages.  
6.1.3  Precision  
Results will generally be reported to 3 significant figures. Percentages will generally be reported 
to 0.1 percentage points. P-values will be reported to two digits when greater than or equal to 
0.095, to three digits when greater than or equal to 0.00095 and less than 0.095, and as <0.001 
for all smaller values.  
6.1.4  Administration  
A test set of tables and figures specified in the S AP will be produced prior to breaking the blind 
using a dummy randomization schedule. The SAP will be finalized and must be approved by the 
Steering Committee prior to the final lock of the trial data and breaking of the blind.  
6.2 Analysis Samples  
The following analysis samples  will be used for testing effectiveness, efficacy , safety, and 
tolerability  endpoints : 
• Intent -to-treat ( ITT) Sample: Participants who are randomized, classified according to their 
randomized treatment assignment . Participants determined to have been ineligible prior to 
randomization , participants who never initiate study drug,  and o bservations made after 
premature permanent discontinuation of study drug are included in this sample.  
• As-treated  (AT) Sample: Participants who are eligible, randomized , and take at least one 
dose of study drug . If a participant permanently discontinues study drug, o bservations made 
during period 1  will be censored follow ing the first visit after study drug discontinuation . 
Separate analyses will clas sify participants  in the AT sample either  according to the actual 
treatment received  or according to the average post-baseline serum urate concentration 
achieved . Participants randomized to inosine who report not taking inosine will be 
reclassified as plac ebo participants. Participants randomized to placebo who report taking 
inosine or whose serum urate during treatment averages 6.5 mg/dL or greater will be 
reclassified as inosine participants . 
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 24 of 34 
 • Safety and Tolerability (ST) Sample: Participants who are rando mized  and take at least one 
dose of study drug , classified according to the actual treatment received . Participants 
determined to have been ineligible prior to randomization and observations made after 
premature permanent discontinuation of study drug are included in this sample.  
The primary efficacy analyses will use the ITT sample to best estimate the expected 
effectiveness of urate -elevating oral inosine supplementation in clinical practice, recognizing that 
compliance in clinical use may differ from com pliance in the clinical trial.  Secondary analyses of 
efficacy outcomes will use the AT sample to best estimate efficacy of inosine supplementation as 
administered and serum urate elevation as achieved.  Analyses of safety and tolerance will use the 
ST sampl e. 
6.3 Baseline Comparison  
While recognizing that any difference observed between treatment groups is axiomatically due to 
chance, nominal  p-values will be calculated as a measure of the magnitude of difference for each 
baseline characteristic summarized using  Fisher's exact tests for nominal variables , exact 
Cochran -Armitage trend tests for ordinal variables,  and two-sample t -tests for approximately 
continuous variables.  
6.4 Sample Size Review  
Estimates of variance components and censoring and drop -out rates requi red for sample size 
calculation will be reviewed periodically using blinded data. No formal sample size re -estimation 
is proposed.  
6.5 Interim Analysis  
Interim analyses for efficacy or futility will be performed by the unblinded statistician using  an 
information -based group -sequential design . Interim analyses will be performed  after approximately 
2000 and 5000 person -months of period 1 follow -up are completed, roughly one -third and three -
quarters of total anticipated period 1 follow -up. Non -binding  early stopping for efficacy will be 
proposed if the active treatment group is superior to placebo for the primary efficacy outcome 
based on a one -sided p -value of 0.001 or less. Other criteria used in deciding whether to stop 
early for efficacy will inclu de evaluation of safety and secondary efficacy outcomes. We propose 
stringent early stopping criteria for efficacy in order to ensure that evidence for efficacy is 
unambiguous if the study is stopped early. Non -binding early stopping for futility will be 
proposed based on a beta -spending rule quadratic in information time. If there were no benefit 
from treatment, then the trial would have a 51% probability of early stopping for futility based 
on this rule. As with the efficacy evaluation, the decision to st op early for futility will also 
include evaluation of feasibility, safety, and secondary efficacy outcomes. Because the efficacy 
and futility stopping rules are non -binding, we conservatively assume that each look is 
cumulative for alpha and ignore possibl e findings of futility when calculating the overall type I 
error.  
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 25 of 34 
 6.6 Efficacy Analysis  
6.6.1  Primary Analysis  of the Primary Efficacy Endpoint  
The primary analysis of the primary efficacy endpoint will estimate the effectiveness to slow PD 
disease progression of or al inosine titrated to achieve serum urate in the range 7.1 to 8.0 mg/dL . 
The analysis will use  the ITT  sample to estimate of rate of change of MDS -UPDRS I -III total 
scores during period 1 in a random slopes model with shared baseline , censoring observatio ns 
made subsequent to initiation of dopaminergic therapy . The model will include fixed terms for  
time, treatment x time, and sex, baseline MAO -B inhibitor use, baseline Schwab and England 
ADL score, and their interactions with time  and random site - and participant -specific intercepts 
and slopes, each with unstructured covariance. Use of a shared baseline adjusts for baseline 
MDS -UPDRS score14,15 in addition to the adjustment for sex, baseline MAO -B inhibitor use , and 
baseline modified Schwab and England ADL score . Inference of benefit from serum urate 
elevation will be made by testing whether the treatment x time interaction term is significantly 
less than zero (i.e., slower progression among subjects randomized to the active arm) using a 
two-sided test a t p < 0.046 for a cumulative two -sided alpha = 0.05.  
This estimate of the effect iveness  of serum urate elevation on MDS -UPDRS will be unbiased if 
observed trajectories are predictive of MDS -UPDRS assessments that are missing due to loss to 
follow -up or are censored due to initiation of dopaminergic therapy. Data from the SURE -PD 
trial sugges t good conformance of UPDRS I -III total score trajectories to the model assumptions. 
No non -linearity in treatment effects on observed UPDRS scores was found and models that 
included quadratic random effects fit worse by Akaike and Bayesian information cri teria. 
Empirical Bayes estimates of 24 -month UPDRS scores assuming linear trajectories were all 
within range of the instrument (range 7.4 to 97.4) even with 85% of the sample being censored 
prior to the final 24 -month observation (median 12 months). Condit ional residuals were normally 
distributed and homoscedastic. Similar assessments and influence statistics will be evaluated in 
judging the adequacy of the proposed primary analysis in this trial.  
6.6.2  Secondary Analyses of the Primary Efficacy Endpoint  
Several secondary analyses will be investigated to assess sensitivity of our estimates of treatment 
effect to alternative modeling  assumption s. 
• Shared -baseline r epeated -measures  model: The fixed effects of time and its interactions will 
be replaced by visit-specif ic fixed effects . The interaction between fixed effects for treatment 
group and visit will be restricted to post -baseline visits by including a numeric indicator 
variable (0 pre -treatment, 1 post -treatment) in the interaction.  The participant -specific 
random intercept s and slopes will be replaced with participant -level unstructured covariance 
among repeated measures.  
• AT sample by treatment group: The primary efficacy model and the secondary repeated -
measures model will be applied to the AT sample, replacing  the treatment group as 
randomized by the treatment actually received.  
• AT sample by serum urate achieved: The primary efficacy model and the secondary 
repeated -measures model will be applied to the AT sample, replacing the treatment group as 
randomized by the average post -baseline serum urate level achieved.  
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 26 of 34 
 • AT sample by change in serum urate: The primary efficacy model and the secondary 
repeated -measures model will be applied to the AT sample, replacing the treatment group as 
randomized by the change from average pre -treatment to average post -baseline serum urate 
level achieved.  
• AT sample by average daily inosine capsule count: The primary efficacy model and the 
secondary repeated -measures model will be applied to the AT sample, replacing the 
treatment grou p as randomized by the daily inosine treatment actually received.  
• AT sample excluding participants who initiate d dopaminergic therapy  by their 12 -week 
(V03) visit : The primary efficacy model and the secondary repeated -measures model will be 
applied to the subset of the AT sample who initiat ed dopaminergic therapy by the ir 12-week 
visit (V03).  
• LEDD -adjusted analysis: The primary efficacy model , the secondary repeate d-measures 
model , and the secondary analyses of the AT sample listed above  will be augmented by 
including observations after initiation of dopaminergic medication and adjusting for time -
dependent LEDD . 
6.6.3  Secondary Efficacy Endpoints  
Continuous secondary effi cacy endpoints will all be analyzed using the ITT and AT sample s and 
the primary and secondary efficacy  analys is described  above . Variables that are strongly right -
skewed will be log -transformed prior to analysis, and estimates will be back -transformed for  
reporting.  
The binary indicator of orthostatic hypotension  will be analyzed in an equivalent generalized 
mixed model treating the indicator variable as a Bernoulli random variable with log it link.  
6.6.4  Disability Warranting Dopaminergic Therapy  
Treatment differences in time to disability warranting dopaminergic therapy during period 1 will 
be tested by a Kaplan -Meier logrank test with a two -sided alpha = 0.05. Participants  lost to 
follow -up will be censored . Note that subjects will continue to be  followed even if they 
discontinue study drug.  
The following  secondary analyses of time to disability warranting dopami nergic therapy will be 
pursued:  
• Subjects lost to follow -up will be classified as initiating dopaminergic therapy a t the time 
of their wit hdrawal.  
• Cox regression will be used to compare treatments with adjustment for baseline modified 
Schwab and England ADL  score . 
6.6.5  Combined Function and Treatment  
A rank -based test of a single outcome combining function as measured by change in MDS -
UPDRS I -III total scores and time to disability warranting dopaminergic therapy will be 
constructed paralleling the Combined Assessment of Function and Survival ( CAFS ) score 
methodology developed for ALS.17 MDS -UPDRS I -III total scores will substitute for ALSFRS -R 
total scores and time to disability warranting dopaminergic therapy will substitute for time to 
mortality. The test consists of calculating a rank -sum score for each individual relative to pair -
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 27 of 34 
 wise comparisons with all other subjects. Subjects are ranked ac cording to time to disability 
warranting dopaminergic therapy when that is observed for both members of a pair or when one 
is censored after the observed event time for the other. Pairs that cannot be ranked by time to 
disability warranting dopaminergic th erapy are ranked by absolute change from baseline in 
MDS -UPDRS I -III total score at the maximum follow -up time at which both subjects have an 
observation. Inference is drawn by calculating a U -statistic from the rank -sum scores.  
6.6.6  Subgroup Analyses  
The foll owing subgroups will be considered: sex, race (classified as Asian, Black or African 
American, Caucasian, or other, including multiracial; or as Caucasian vs. non -Caucasian if fewer 
than 10% of our sample is non -Caucasian), ethnicity (classified as Hispani c or Latino vs. non -
Hispanic), use of MAO -B inhibitors at baseline, and age (both categorized as <65 years vs. ≥65 
years and continuous).  For each subgroup, t he potential for differential benefit from serum urate 
elevation will be tested by including subgr oup, subgroup x time, and subgroup x time x treatment 
interaction terms into the primary random -slopes model. A significant subgroup x time x 
treatment 3 -way interaction in combination with significantly slower progression among 
members of a subgroup rando mized to serum urate elevation vs. members of the same subgroup 
randomized to placebo will be taken as evidence of differential benefit. For sex, we will also test 
for sex-specific effects in selected  secondary analyses  of efficacy, disability warranting 
dopaminergic therapy, and symptomatic effects  and in safety analyses related to kidney stone 
risk. For safety analyses, we will also summarize and compare eligible vs. the few ineligible 
participants in the ST sample.  
6.6.7  Pharma cogenetics  
The above listed and any subsequently designated  genetic variants  will be tested  as potential 
modifiers of treatment effect . For each genetic variant , the potential for differential benefit from 
serum urate elevation will be tested by including genotype , genotype  x time, and genotype  x time 
x treatment interaction terms into the primary random -slopes model. A significant genotype  x 
time x treatment 3 -way interaction in combination with significantly slower progression among 
members of a genotype  randomized to serum urate elevation vs. participants with  the same 
genotype  randomized to placebo will be taken as evidence of differential benefit.  
6.6.8  Symptomatic Effects  
The presence of symptomatic effects will be tested using a change -point model construct ed as a 
partial linear spline over time with knots at 12 weeks and 24 months. Both fixed and subject -
specific random terms for intercept, slope from baseline to 12 weeks, slope from 12 weeks to 24 
months, and slope from 24 to 27 months (or from V10 -equival ent visit on study drug to SV) will 
be included. Unstructured covariance will be assumed among the random effects (10 terms). The 
AT sample will be analyzed. Significantly smaller slopes during wash -in or larger slopes during 
wash -out among subjects treated with inosine using one -sided testing at alpha = 0.025 will be 
interpreted as symptomatic effects. If symptomatic effects are not found on that basis, the 
absence of symptomatic effects will be judged based on a non -inferiority test using a non -
inferiority bound of 6.3 / 3 = 2.1 points /month in the direction of a symptomatic effect and using 
one-sided testing at alpha = 0.05.  
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 28 of 34 
 6.6.9  Disease Modification  
A three -part test of time to disability warranting dopaminergic therapy will be used to evaluate 
whether serum urate elevation is disease -modifying18-20. Inference of disease modification would 
be supported if (a) a Kaplan -Meier logrank test of time to disability warranting dopaminergic 
therapy during period 1 favors serum urate elevation, (b) the proportion of subjects who 
developed disability  warranting dopaminergic therapy remains significantly lower  among those  
randomized to serum urate elevation vs. placebo at the end of period 2 by Chi -square test, and (c) 
the time -dependent hazard ratio for time to disability warranting dopaminergic thera py during 
period 2 is non -inferior to a rate that would lead to equivalence to placebo by 3 months by Cox 
regression. Inference from each of the three component tests will be evaluated sequentially. 
Difference in time to disability warranting dopaminergic therapy will be evaluated first. If 
significant by logrank test with two -tailed alpha = 0.05, then the proportion not yet requiring 
dopaminergic therapy at the end of period 2 will be tested second. If significant by Chi -square 
test with two -tailed alpha =  0.05, then non -inferiority of the time -dependent hazard ratio will be 
tested by Cox regression based on a one -tailed test at alpha = 0.05.  
6.6.10  Multiplicity Adjustments  
With two interim efficacy analyses each testing for benefit of serum urate elevation at a one-
sided p < 0.001, the f inal primary analysis tested using a two -sided p < 0.046 ensures that the 
overall type I error rate is under 5%.  Results from analysis of secondary efficacy endpoints  and 
subgroup analyses  will report nominal, comparison -wise p -values, recognizing that the totality of 
results will be evaluated in judging the potential efficacy of serum urate elevation . 
6.6.11  Missing Data  
Baseline values for efficacy endpoints  will be determined from the last non -missing data 
collected prior to the first dose of study medication.  The planned mixed  model yields estimates 
that are unbiased conditional on the observed scores  under a missing at random assumption . In 
addition, a secondary analysis of the primary endpoint will use placebo -based multiple 
imputation of missing data. Additional sensitivity analyses may be pursued to impute missing 
values or otherwise construct models for unobserved outcomes  if more than  20% of participants 
are missing follow -up data for any reason . 
6.7 Safety and Tolerability Analysis  
6.7.1  Treatment -emergent Adverse Events  
The incidence of TEAEs will be summarized by the number of events of a given classification 
experienced by participants in ea ch treatment group and by the number and proportion of 
participants experiencing such an event in each  treatment group  in the ST sample . TEAEs will be 
summarized in aggregate across all MedDRA terms and separately by MedDRA system organ 
class and preferred term.  
Aggregate summaries of TEAE grade will include  characteristics of : (a) seriousness, (b) severity, 
(c) relatedn ess to study drug, (d) action taken with study drug, (e) action taken with study 
procedure, and (f) outcome . For each level of a given TEAE characteristic, summaries will 
include the number of events of a given classification and by the number and proportion of 
participants for which that level of a characteristic was the worst they experienced  (treating any 
unknown characteristic as not worst) .  
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 29 of 34 
 6.7.2  Safety Labs  
The absolute level and the absolute change from baseline for each safety laboratory assay will be 
summarized as means, standard deviations, medians, and ranges at each visit by treatment group.  
The proportio n of participants with safety lab levels below the lower limit of normal or above the 
upper limit of normal will be summarized by treatment group  by visit and at any post -baseline 
visit. 
6.7.3  Vital Signs  
The absolute level and the absolute change from baseline for vital signs will be summarized as 
means, standard deviations, medians, and ranges at each visit by treatment group.  
6.7.4  Additional Continuous Safety Outcomes  
The additional continuous safety outcomes  of weight, ECG parameters, and their absolute 
change from baseline will be summarized as means, standard deviations, medians, and ranges at 
each visit by treatment group  and tested for group differences in linear mixed models . 
6.7.5  Tolerability  
Participants wi ll be classified  as tolerant, intolerant, or censored with subjects lost to follow -up 
or withdrawing consent prior to administrative termination classified as intolerant. Tolerability 
will then be estimated from Kaplan -Meier product -limit methods with comp lementary log -log 
confidence bounds at 12 weeks , 12 months,  and 24 months. Serum urate elevation will be 
declared tolerable at each time point if its one -sided lower 95% confidence bound is greater than 
50%. We will explore the relationship between toleran ce and use of dopaminergic therapy using 
Cox regression with use of dopaminergic therapy as a time -dependent covariate.  
6.7.6  Alkalinization  and Nephrolithiasis  
The frequency of persistent acid ic urine will be summarized by treatment group and tested by 
Fisher's  exact test  in the ST sample . The efficacy of the alkalinization protocol to increase urine 
pH will be summarized  overall in the ST sample. The frequency of nephrolithiasis and the 
absolute rate of nephrolithiasis per time exposed to study drug will be summarized by treatment 
group. Risk factors for nephrolithiasis will be tested in a binary generalized linear model with log 
link and with log time on study drug as an offset. The following risk factors will be tested  in a 
multivariable model:  
• age,  
• sex,  
• treatment,  
• uric acid excretion fraction at baseline estimated from serum urate and 24 -hr urine  urate ,  
• uric acid crystals/hpf  prior to first nephrolithiasis  
o in most recent urinalysis,  
o average in post -randomization urinalyses,  
o maximum in any urinalysis,  
• urine specific gravity  prior to first nephrolithiasis  
o in most recent urinalysis,  
o average in all urinalyses,  
o maximum in any urinalysis,  
• urine pH prior to first nephrolithiasis  
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 30 of 34 
 o in most recent urinalysis,  
o average in all urinaly ses, and  
o minimum in any urinalysis . 
6.8 Other Analyses  
6.8.1  Participant  Disposition  
The number of participants  who were screened, randomized, completed scheduled follow up, and 
prematurely withdrew study participation will be summarized overall and by treatment group. 
Reasons for screen failure and for withdrawal from study will be presented.  
6.8.2  Study Drug Exposure  
The number of capsules of  study drug  prescribed will be summarized by visit and treatment 
group. Total study drug exposure will be calculated and will be summarized by treatment group. 
Compliance with study drug  will be calculated as the number of doses tak en divided by the 
scheduled number of doses taken  prior to permanent discontinuation , expressed as a percentage.  
6.8.3  Prior and Concomitant Medication Use  
Concomitant medications taken during the study period will be listed for each participant , coded 
using the World Health Organization Drug Dictionary Enhanced. The percentage of participants  
taking each class of medication  will be summarized overall and by treatment group.  
6.8.4  Determinants of change in MDS -UPDRS  
Potential determinants  of change in MDS -UPDRS  will be tested  to assess their relationship to 
PD progression  independent of serum urate elevation. This may motivate f urther adjustment of 
the primary model  as additional secondary analyses  and may also assist in the design of future 
trial. In addition to those noted above in 6.6.1 , we will test the following:  
• Prodromal PD features, either individually or as an index  
o Positive RBD screen at SC1 or BL  
 RBD characterization: At SC1 , do those who are RBD -positive vs 
negative (2 vs . 1 on Q1 of RBD Slee p Question) have higher age - and sex -
adjusted serum urate?  
o Positive hyposmia screen: Response of 1 on Q9a of the PD Risk Factor 
Questionnaire  
 Hyposmia characterization: Do hyposmics (1 on Q9 a vs. 0 on Q9) have 
lower age - and sex- adjusted BMI at SC2?  
o Posit ive constipation screen: Response of >2 on Q1.11 of MDS -UPDRS at SC2 or 
daily (non -prn) laxative use on concomitant medication log at SC2  
 Constipation characterization: Do those who are positive by this 
moderately stringent criterion have a:  
• Lower current,  vigorous physical activity score (Q3 on PD Risk 
Factor Questionnaire; among those selecting response 1 -4)? 
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 31 of 34 
 • Lower caffeine intake (Q3 -4 on Smoking, Alcohol and Caffeine 
Status)  
o SURE -PD3 prodromal PD Index (range 0, 1, 2 or 3) with simple sum values for 
presence (= 1) for each of above three features.  
6.8.5  Determinants of Early Disability Warranting Dopaminergic Therapy  
An earlier, mid -study effort to identify determinants of need for do paminergic therapy occurring 
prematurely (by the 12 -week visit) was prompted by a higher than expected rate of these events 
and a concern that it would reduce  study power to meet its primary analysis objective.  Modified 
Schwab and England  ADL score at scre ening was identified as a significant predictor , and site 
staff were advised to keep in mind that a Modified Schwab and England ADL score below 90% 
was predictive of premature need for dopaminergic therapy, the expectation of which is an 
exclusionary crite rion. Because this clinical eligibility criterion is common in PD trials of 
candidate neuroprotectants, a fuller assessment of predictors would be valuable .  
The following potential determinants of Early Disability Warranting Dopaminergic Therapy  will 
be tested: Modified Schwab and England ADL score, time between symptom onset or diagnosis 
and baseline visit, having taken dopaminergic medication (other than an MAO -B inhibitor) prior 
to screening, being on a stable dosage of an MAO -B inhibitor at b aseline, baseline MDS -UPDRS  
Part I -III total score , DaTscanTM SBR, expectation of improvement on inosine (on Expectancy 
Questionnaire), baseline Neuro -QOL Depression score , and baseline MoCA  score . 
6.8.6  Placebo Response  
The frequency of a placebo -associated imp rovement in activities of daily living (ADL) and 
motor symptoms as measured by the MDS -UPDRS Part s IB and II and Part III, respectively, will 
be summarized among all placebo arm participants , by visit , and by site . Following Goetz et al. 
2000 , we will defi ne placebo -associated improvement as a reduction  in the ADL or  motor score 
of at least 50% or a n improvement from baseline  of two or more points on at least two different  
items of the respective MDS -UPDRS scale . Stability  of the rates of placebo -associated  
improvements  will be tested across visits using mixed model logistic regression with fixed 
effects of visit and random participant -specific intercepts . The following predictors of placebo -
associated improvement at any visit will be tested by logistic regr ession:  
• age at baseline (less than 65 years versus greater  or equal to 65 years ),  
• disease duration  at baseline (less than 2 years  vs. greater or equal to 2 years ),  
• disease severity  at baseline (modified Hoehn and  Yahr Sta ges 1 and 1.5 vs. 2 and 2.5) , 
• number of years education (Q1 on Socio -Economics form)  
• daily caffeine intake : lower vs higher (Q3 + 0.3xQ4 from Smoking, Alcohol and Caffeine 
form)   
• expectation of inosine : “A lot better” vs “Somewhat better” vs “No change” or worse  (Q2 
on PD -Expectancy ques tionnaire)  
• expectation of inosine -placebo difference :  >/=2 vs <2 units more favorable for inosine 
(Q2 - Q1 on PD -Expectancy questionnaire)  
• preference for inosine: “strong” vs other (Q3 on PD-Expectancy questionnaire)  
• treatment belief: placebo vs inosine  (Q2 on Blindedness Questionnaire) . 
 
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 32 of 34 
 6.8.7  Blindedness  
Descriptive stats will be summarized for responses on the early and late administrations of the 
Blindedness Questionnaire and the change between them. The following predictors of  treatment 
assignment belief r eported on the  Blindedness Questionnaire will be tested by logistic regression . 
For belief of inosine assignment (stratified by correct and incorrect):  
• age at baseline (categorized as < 65 years vs. ≥ 65 years ) 
• sex 
• treatment  assig nment  
• MDS -UPDRS I -III censored change at wash -in (per 6.6.8) for response at the 6-week 
(V02) administration  
• MDS -UPDRS I -III censored change to ~24 -mo/V10 for response at the ~24-mo/V10  
administration  
• history  of preceding nephro -lithiasis TEAE  
• history  of preceding gout, gout -like or other arthritic TEAE  
• average preceding daily number study drug capsules  
• expectation of inosine: “A lot better” vs “Somewhat better” vs “No change” or worse (Q2 
on PD -Expectancy questionnaire),  
• expectation of inosine -placebo  difference:  >/=2 vs <2 units more favorable for inosine 
(Q2 - Q1 on PD -Expectancy questionnaire)  
• preference for inosine: “strong” vs other (Q3 on PD -Expectancy questionnaire).  
7. References  
1. Hauser RA, Auinger P; Parkinson Study Group. Determination of minim al clinically 
important change in early and advanced Parkinson's disease. Mov Disord. 2011 
Apr;26(5):813 -8. 
2. Lang  AE, Eberly S, Goetz CG, Stebbins G, Oakes D, Marek K, Ravina B, Tanner CM, 
Shoulson I; LABS -PD investigators. Movement Disorder Society Unified  Parkinson  Disease 
Rating Scale experiences in daily living: Longitudinal changes and correlation with other 
assessments. Mov Disord . 2013 Dec;28(14):1980 -6. 
3. Goetz  CG, Stebbins GT, Tilley BC. Calibration  of unified Parkinson's disease rating scale 
scores t o Movement Disorder Society -unified Parkinson's disease rating scale scores. Mov 
Disord. 2012 Sep 1;27(10):1239 -42. 
4. Gallagher DA, Goetz CG, Stebbins G , Lees AJ, Schrag A. Validation of the MDS -UPDRS 
Part I for nonmotor symptoms in Parkinson's disease. Mov Disord. 2012 Jan;27(1):79 -83. 
5. Stebbins  GT, Goetz  CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC. How to identify tremor 
dominant and postural instability/gait difficulty groups with the movement disorder society 
unified Parkinson's disease rating scale: compa rison with the unified Parkinson's disease 
rating scale. Mov Disord . 2013 May;28(5):668 -70. 
6. Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, 
Rudolph, A, Bogdanov M, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes 
D, Fahn S, Shoulson I,  
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 33 of 34 
 7. Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, & 
Ascherio A, and the Parkinson Study Group PRECEPT Investigators.  Serum urate as a 
predictor of clinical and radiographic progression in Parkinson’s disease.  (2008) Arch 
Neurol. 65:716 -723. 
8. The Parkinson Study Group SURE -PD Investigators; Schwarzschild MA, Ascherio A, Beal 
MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin  EA, Oakes  
D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, Gartner M, Hung A, Bwala G, Lenehan 
R, Encarnacion E, Ainslie M, Castillo R, Togasaki D, Barles G, Friedman JH, Niles L, 
Carter JH, Murray M, Goetz CG, Jaglin J, Ahmed A, Russell DS, Cotto C, Goudreau JL, 
Russell D, Parashos SA, Ede P, Saint -Hilaire MH, Thomas CA, James R, Stacy MA, 
Johnson J, Gauger L, Antonelle de Marcaida J, Thurlow S, Isaacson SH, Carvajal L, Rao J, 
Cook M, Hope -Porche C, McClurg L, Grasso DL, Logan R, Orme C, Ross T, Brocht AF, 
Constantin escu R, Sharma S, Venuto C, Weber J, Eaton K. (2014). Inosine to Increase 
Serum and Cerebrospinal Fluid Urate in Parkinson Disease: A Randomized Clinical 
Trial.  JAMA Neurol . 2014 Feb 1;71(2):141 -50. [Published online 2013 Dec 23.]  
9. Parkinson Study Group. Ef fect of deprenyl on the progression of disability in early 
parkinson's disease. N Engl J Med 1989;321(20):1364 -71. 
10. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability 
in early Parkinson's disease. N Engl J Med 1993;32 8:176 -83. 
11. Parkinson Study Group PRECEPT Investigators. (2007) Mixed lineage kinase inhibitor 
CEP-1347 fails to delay disability in early Parkinson disease. Neurology. 69:1480 -1490.  
12. Schoenfeld, DA. 2014. A program to calculate the power or sample size for a  random slopes 
model. MGH Biostatistics Center. Available 
at: http://hedwig.mgh.harvard.edu/biostatistics/node/42   (Accessed online 9/5/15).  
13. Weaver et al. Randomized trial of deep brain st imulation for Parkinson disease: Thirty -six-
month outcomes. Neurology. 2012;79:55 -65.  
14. Liang KY, Zeger S. Longitudinal data analysis of continuous and discrete responses for pre –
post designs. Sankhyā: The Indian Journal of Statistics (Series B) 2000; 62(1) :134–148. 
15. Liu GF, Lu K, Mogg R, Mallick M, Mehrotra DV. Should baseline be a covariate or 
dependent variable in analyses of change from baseline in clinical trials? Stat Med. 2009 Sep 
10;28(20):2509 -30. 
16. Goetz CG, Luo S, Wang L, Tilley BC, LaPelle NR, Stebb ins GT. Handling missing values 
in the MDS -UPDRS. Mov Disord. 2015 Oct;30(12):1632 -8. 
17. Berry  JD, Miller R, Moore DH, Cudkowicz ME, van den Berg LH, Kerr DA, Dong Y, 
Ingersoll EW, Archibald D. The Combined Assessment of Function and Survival ( CAFS ): a 
new en dpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 
2013 Apr;14(3):162 -8. 
18. Leber P. Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Dis 
Assoc Disord . 1997;11 Suppl 5:S10 -21; discussion S37 -9. 
19. McDermot t MP, Hall WJ, Oakes D, Eberly S. Design and analysis of two -period studies of 
potentially disease -modifying treatments. Control Clin Trials . 2002 Dec;23(6):635 -49. 
SURE -PD3: Statistical Analysis Pla n Version 1.0, 05 Sep 2019  
 Page 34 of 34 
 20. Rascol O. "Disease -modification" trials in Parkinson disease: target populations, endpoints  
and study design. Neurology . 2009 Feb 17;72(7 Suppl):S51 -8. 
21. Zadikoff C, Fox SH, Tang -Wai DF, Thomsen T, de Bie RM, Wadia P, Miyasaki J, Duff -
Canning S, Lang AE, Marras C. A comparison of the mini mental state exam to the 
Montreal cognitive assessment in i dentifying cognitive deficits in Parkinson's disease. Mov 
Disord. 2008 Jan;23(2):297-9. 
22. Parkes JD, Baxter RC, Marsden CD, Rees JE. Comparative trial of benzhexol, amantadine, 
and levodopa in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1974 
Apr;37(4):422 -6. 
23. Mancini F, Di Fonzo A, Lazzeri G, Borellini L, Silani V, Lacerenza M, Comi C. Real life 
evaluation of safinamide effectiveness in Parkinson's disease. Neurol Sci. 2018 
Apr;39(4):733 -739. 
 